Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is
crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such …

Digital technologies are being harnessed to support the public-health response to COVID-
19 worldwide, including population surveillance, case identification, contact tracing and …

A novel coronavirus, which has been designated as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background Little is known about the nature and durability of the humoral immune response
to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods …

Background The relationship between the presence of antibodies to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection …

Coronaviruses are an extensive family of viruses that can cause disease in both animals
and humans. The current classification of coronaviruses recognizes 39 species in 27 …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

A key goal to controlling coronavirus disease 2019 (COVID-19) is developing an effective
vaccine. Development of a vaccine requires knowledge of what constitutes a protective …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects …